Innate Pharma updates pipeline timelines in Q3 2026 report
Innate Pharma reported progress on its Nectin-4 ADC, lacutamab and monalizumab programs alongside a cash position of €96.8 million as of September 30, 2026.
SEC filing
Latest
2 stories
Thursday, November 5
Tuesday, October 27
Innate Pharma pushes PACIFIC-9 data readout to first half of 2027
AstraZeneca delayed the Phase 3 trial's high-level data readout by roughly six months, citing the study's event-driven design.
SEC filing